2003, Number s1
<< Back Next >>
Arch Cardiol Mex 2003; 73 (s1)
Arterial hypertension and diabetic nephropathy
Herrera AJ
Language: Spanish
References: 12
Page: 66-69
PDF size: 51.94 Kb.
ABSTRACT
Diabetic nephropathy (DN) is the most common cause of chronic renal failure (CRF), in Mexico prevalence of diabetes is higher than other countries. Genetic susceptibility, arterial hypertension, proteinuria and initial hyperfiltration are risk factors for CRF. Renal injury is mediated by protein glycation, proteinuria and hemodynamics alterations induced by arterial hypertension and impaired renal autoregulation. Angiotensin II is directly involved in renal injury through its hemodynamic effects, oxidative stress, induction of proinflammatory and profibrotic factors and cellular proliferative effect. Prospective, well controlled clinical trials in patients with type 1 and type 2 DM have shown that interrupting the renin angiotensin system with CEI or ARA effectively prevent progression of DN. Combination of both drugs may provide further nephroprotection. Antihypertensive therapy in patients with DN must include CEI or ARA and to reduce BP below 130/85 mmHg and if proteinuria is present, under 120/75.
REFERENCES
Velázquez-Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelín Hernández G, Castillo C, Attie F, Tapia Conyer R: Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México. Arch Cardiol Mex 2003; 73:62-772.
Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med, 2002; 346: 1145-1151.
Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213.
Ritz E, Stefanski A: Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27: 167.
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 1557.
de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH: Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993.
Rajagopalan S, Krirz S, Münzel T, Tarpay M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996; 97: 1916-1923.
Barnes PJ, Karin M: Nuclear factor kB. A pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 1997; 336: 1066-1071.
Lewis, EJ, Hunsicker, LG, Bain, RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, et al: For the collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al: for; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440.
Full text